MacroGenics, Inc. (NASDAQ:MGNX) will be discussing 3Q20 financial results with the investment community.on 4th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.macrogenics.com
Earnings Expectation
MacroGenics, Inc. is expected to report third quarter earnings results, after market close, on Wednesday 4th November 2020. Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.93 per share from revenue of $ 15.79 million. Looking ahead, the full year loss are expected at $ 3.64 per share on the revenues of $ 68.09 million.
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapeutics for the treatment of cancer in the United States. Its pipeline of immuno-oncology product candidates includes Margetuximab, a monoclonal antibody, which is in Phase III clinical trial that targets HER2-expressing tumors, such as various breast and gastroesophageal cancers. The company is also developing Flotetuzumab, a DART molecule that recognizes CD123 and CD3; MGA012, an anti-PD-1 monoclonal antibody, which inhibits programmed cell death protein 1 (PD-1); MGD013, a monoclonal antibody that targets the immune checkpoints PD-1 and lymphocyte-activation gene 3; MGD019, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; and Enoblituzumab, a monoclonal antibody that targets B7-H3.
